Revvity RVTY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Segment revenue by Business | ||||||
| Diagnostics | $1.45B+6.0% | $1.42B+5.1% | $1.39B+14.7% | $1.38B+12.1% | $1.37B+8.6% | |
| Life Sciences | $1.45B+3.6% | $1.43B+2.3% | $1.42B-5.7% | $1.42B-4.0% | $1.4B-4.4% | |
| Segment Cost of Revenue by Business | ||||||
| Diagnostics | $655.33M+12.9% | $633.77M+10.0% | $604.46M+8.1% | $590.21M+7.0% | $580.46M+7.0% | |
| Life Sciences | $528.55M+9.2% | $516.3M+5.8% | $510.98M+4.5% | $498.55M-0.1% | $483.95M-4.4% | |
| Segment operating income by Business | ||||||
| Diagnostics | $346.27M-1.6% | $344.17M-2.8% | $343.95M+2.0% | $348.42M+9.6% | $351.75M+17.4% | |
| Life Sciences | $456.53M-3.3% | $458.26M-1.9% | $460.42M+0.7% | $469.94M-1.0% | $472.04M-2.7% | |
| Segment research and development expenses by Business | ||||||
| Diagnostics | $104.52M+13.9% | $103.58M+15.1% | $96.02M+2.9% | $95.52M-1.4% | $91.77M-10.0% | |
| Life Sciences | $115.39M+8.3% | $112.03M+7.3% | $110.5M+5.2% | $108.64M+2.3% | $106.59M0.0% | |
| Segment Selling, general and administrative expenses by Business | ||||||
| Diagnostics | $343.73M+0.1% | $343.43M+2.2% | $345.07M+3.0% | $344.46M+2.4% | $343.41M+1.5% | |
| Life Sciences | $352.09M+3.6% | $344.52M+1.7% | $341.98M+1.5% | $342.73M+2.6% | $339.91M+2.4% | |
| Foreign currency translation by Business | ||||||
| Diagnostics | $24.59M— | $48.65M— | —— | —— | —— | |
| Life Sciences | $57M+614% | $115.58M+349% | $39.58M-39.0% | $85.57M+668% | $7.99M+652% | |
| Goodwill by Business | ||||||
| Diagnostics | $7.66B— | $7.73B— | $7.79B— | —— | —— | |
| Life Sciences | $18.78B— | $18.61B— | $18.4B— | —— | —— | |
| Depreciation by Business | ||||||
| Diagnostics | $36.12M+2.6% | $33.4M-7.4% | $35.44M+7.3% | $35.5M+8.6% | $35.22M+6.1% | |
| Life Sciences | $36.21M+24.7% | $33.49M+11.1% | $29.25M-10.3% | $29.47M-6.3% | $29.04M-5.9% | |
| Lease Abandonment Charges Included In Restructuring and Other Costs by Business | ||||||
| Diagnostics | $1.8M— | $800K— | —— | —— | —— | |
| Life Sciences | $5.95M— | $6.2M— | —— | —— | —— | |
| Segment revenue by Geography | ||||||
| Americas | $1.27B+2.8% | $1.26B+2.7% | $1.25B+4.0% | $1.25B+4.4% | $1.23B+2.1% | |
| Asia | $768.85M-2.8% | $775.11M-1.8% | $774.01M-0.6% | $784.42M+0.9% | $790.66M+1.8% | |
| Europe | $866.23M+16.1% | $824.98M+11.1% | $785.25M+6.5% | $764.89M+4.3% | $745.84M+0.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Revvity break its business down?
- Revvity (RVTY) reports segment revenue by business across 2 parts — Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Revvity's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Revvity's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
